Month: October 2023

Research has repeatedly shown that positive relationships improve quality of life for breast cancer patients. Having strong social supports is known to decrease depression and anxiety in people with advanced cancer—but friends and family are often unprepared to provide this support.  Once cancer has spread, or metastasized, to other areas of the body, it is
0 Comments
Taletrectinib also shrank tumors in 57 percent of people with ROS1-positive NSCLC who had previously been treated with a ROS1 TKI in the trial Taletrectinib continues to be generally well tolerated with low incidence of neurological adverse events Interim TRUST-II results are consistent with data previously reported from TRUST-I trial NEW YORK, NY, October 21,
0 Comments
After endocrine therapy, the most common prior treatments for patients in the datopotamab deruxtecan and chemotherapy arms, respectively, included one (63%, 61%) to two (37%, 38%) lines of chemotherapy and CDK4/6 inhibitor inhibitors (82%, 78%). At the 17 July 2023 data cut-off, 93 patients remained treatment with datopotamab deruxtecan and 39 remained on chemotherapy. AstraZeneca
0 Comments
MADRID, October 23, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 3 MARIPOSA study showing RYBREVANT® (amivantamab-vmjw) in combination with lazertinib compared to osimertinib resulted in a 30 percent reduction in the risk of disease progression or death (Hazard Ratio [HR]=0.70; 95 percent Confidence Interval [CI], 0.58–0.85;
0 Comments
MADRID, October 23, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 3 MARIPOSA-2 study showing the regimen of RYBREVANT® (amivantamab-vmjw) given with or without lazertinib and combined with chemotherapy reduced the risk of disease progression or death by 56 and 52 percent respectively (Hazard Ratio [HR]=0.44; 95
0 Comments
TROPION-Lung05 resultsInitial results from the TROPION-Lung05 Phase II trial showed datopotamab deruxtecan demonstrated encouraging antitumour activity in patients with heavily pretreated locally advanced or metastatic NSCLC with actionable genomic alterations including those with EGFR mutations and anaplastic lymphoma kinase (ALK) rearrangements. These data were presented at the ESMO 2023 Congress on Saturday, 21 October (1314MO).
0 Comments
IRVINE, Calif., Oct. 24, 2023 /PRNewswire/ — Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced positive topline results from two pivotal Phase 3 clinical studies evaluating trenibotulinumtoxinE (BoNT/E) for the treatment of moderate to severe glabellar lines (M21-500 and M21-508). The Phase 3 multicenter, randomized, double-blind, placebo-controlled studies evaluated the safety and efficacy of
0 Comments
PRINCETON, N.J.–(BUSINESS WIRE) Oct 24, 2023 — Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for BMS-986278, a potential first-in-class, oral, lysophosphatidic acid receptor 1 (LPA1) antagonist, for the treatment of progressive pulmonary fibrosis (PPF), a devastating, life-threatening illness. Currently, there is only
0 Comments
mRNA-1083 is Moderna’s first respiratory combination vaccine candidate to enter a Phase 3 trial Phase 3 initiation follows data from a Phase 1/2 trial where mRNA-1083 showed strong immunogenicity against influenza and COVID-19, with an acceptable reactogenicity and safety profile, compared to licensed standalone vaccines Company has multiple programs in Phase 3 development across several
0 Comments
HALIFAX, NS, Oct. 25, 2023. ABK Biomedical, Inc., an innovative, medical device company dedicated to the research, development, and commercialization of advanced imageable embolic medical devices, today announced the first patient treated in its Route90 US IDE Pivotal study. The Eye90 microspheres radioembolization procedure was performed by Eric A. Wang, MD, FSIR, with Charlotte Radiology
0 Comments
REYKJAVIK, Iceland , Oct. 26, 2023. A large international study led by deCODE Genetics on the genetics of migraine provides novel insights into the biology of migraine enabling detection of rare variants protecting against migraine, opening an avenue for potential development of novel drug targets. In a study published today in Nature Genetics a group
0 Comments
A diverse research community which represents the breadth of our population is vital if we want to be confident we have the best talent addressing the full range of questions in cancer research, the answers to which will lead to the best outcomes for everyone. But right now, the cancer research sector doesn’t represent the
0 Comments
Tackling inequalities in healthcare is something that I’ve always been passionate about.   I am, and always have been a proud Yorkshireman – I grew up in Barnsley and most of my family still live there. But my upbringing there made me very much aware of the impact that socioeconomic deprivation can have on the health
0 Comments
The fact a species’ cancer risk doesn’t increase with its size is called Peto’s paradox, after Professor Sir Richard Peto, one of our researchers, who first laid it out in the 1970s.  If we can solve the paradox – and learn how the world’s biggest animals avoid cancer – we‘ll have a much better idea
0 Comments
In this article NOVO.B-DK LLY Follow your favorite stocksCREATE FREE ACCOUNT George Frey | Reuters Most analysts predict the market for new weight loss drugs like Wegovy and Mounjaro will be enormous, but estimates vary for its exact size depending on who you ask. On Monday, Citi raised its estimate for incretin drug sales to
0 Comments
Woman with Signos wearable and app Source: Signos Weight loss has always been big business, but it’s exploded of late due to surging demand for Ozempic, Wegovy and other new diabetes and obesity drugs. In the first half of 2023, sales of Ozempic and Wegovy rose by 58% and 363%, respectively. That’s after quarterly prescriptions
0 Comments
In this article WMT AMZN Follow your favorite stocksCREATE FREE ACCOUNT Photo courtesy of Amazon Amazon is considering an expansion into veterinary telehealth in its latest bid to compete with Walmart, which began offering the service to Walmart+ subscribers earlier this year, people familiar with the matter told CNBC.  The e-commerce giant, which has already
0 Comments
We’re buying 30 shares of Danaher (DHR) at roughly $199 each. Following Tuesday’s trade, Jim Cramer’s Charitable Trust will own 550 shares of DHR, increasing its weighting in the portfolio to 4.08% from 3.87%. Danaher reported a better-than-expected third-quarter Tuesday morning, but the stock is under pressure in early trading due to uncertainty around the
0 Comments